Stock EOLS EVOLUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
12.4 USD -4.62% Intraday chart for Evolus, Inc. -1.67% +17.76%
May. 20 Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse? Dermal Filler Products at 2024 SCALE Meeting CI
May. 11 Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evolus : Scientific Investor Presentation
PU
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
BU
Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse? Dermal Filler Products at 2024 SCALE Meeting
CI
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit
AQ
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
BU
Evolus Sandra Beaver Named Orange County Business Journal s Public Company CFO of the Year
AQ
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.
CI
Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.
CI
Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.
CI
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
BU
Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Evolus, Inc., Q1 2024 Earnings Call, May 07, 2024
Evolus Reports First Quarter 2024 Results and Provides Business Update
BU
Earnings Flash (EOLS) EVOLUS Reports Q1 Revenue $59.3M, vs. Street Est of $57.3M
MT
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024
CI
AbbVie raises annual profit forecast on strong Skyrizi sales
RE
Evolus to Report First Quarter Financial Results on May 7, 2024
BU
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. News Evolus, Inc.